Spero Therapeutics, Inc.

NASDAQ:SPRO

Biotechnology

Healthcare
$0.87 +3.79%

+$0.08 today

Market cap
$50.92M
Beta
1.46
P/E (TTM)
8.2
EPS (TTM)
$0.27
52W Low $1.80High $3.22

Volume 0.27M

Average 0.78M

SPRO Pre-Tax Margin

Income before tax as a percentage of revenue.

Spero Therapeutics, Inc.NASDAQ: SPRO

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin narrows to -2791.9%

Pre-tax margin was -2791.9% in Q1 FY2026, down 2555.8 pp from a year earlier. On a trailing-twelve-month basis it was 28.3%, up 184.8 pp year over year. Over 3 fiscal years it widened by 110.4 pp.

Context

  • Pre-tax margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-2791.9%-2872.0 pp QoQ
Last fiscal yearDec 2025
14.8%+157.7 pp YoY
LTMMar 2026
28.3%+184.8 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-2555.8 pp——
1 year+157.7 pp——
3 years+110.4 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
14.8%
Year-over-year change
+157.7pp

Pre-Tax Margin vs competitors

How SPRO compares with its peers on the latest reported figures

  • SPRO's LTM Mar 2026 pre-tax margin of 28.3% is the highest of the 5 companies compared; the peer median is -2490.6%.
  • Its year-over-year change of +184.8 pp is the highest of 4, against a peer median of -462.9 pp.
  • Over three fiscal years its change of +110.4 pp compares with a peer median of -395.0 pp.
SPRO Competitors Peer median
Pre-Tax Margin for SPRO and competitors
Company Period LTM level YoY 3-year change
SPROSpero Therapeutics, Inc.LTM Mar 202628.3% +184.8 pp+110.4 pp
SEERSeer, Inc.LTM Mar 2026-468.0% +96.8 pp+177.7 pp
IRDOpus Genetics, Inc.LTM Mar 2026-892.4% -462.9 pp-395.0 pp
MCRBSeres Therapeutics, Inc.LTM Mar 2026-4088.8% ——
INOInovio Pharmaceuticals, Inc.FY2025-130000.0% -80745.7 pp-127273.3 pp
HURATuHURA Biosciences, Inc.FY2025— ——
CRBPCorbus Pharmaceuticals Holdings, Inc.FY2025— ——
CGTXCognition Therapeutics, Inc.FY2025— ——
ABOSAcumen Pharmaceuticals, Inc.FY2025— ——
ACTUActuate Therapeutics IncFY2025— ——
Peer median (excluding SPRO) -2490.6%-462.9 pp-395.0 pp

Competitors are the stored peer set for SPRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.07M48.58M103.78M47.98M59.62M
Cost of Revenue0051.44M96.76M0
Gross Profit3.07M48.58M52.34M(48.78M)59.62M
Gross Margin100.0%100.0%50.4%-101.7%100.0%
Research & Development64.53M47.59M51.44M96.76M38.47M
Selling, General & Admin41.7M36.48M25.55M23.7M21.18M
Operating Expenses91.04M90.78M30.86M24.58M59.64M
Depreciation & Amortization646K869K367K2K0
EBITDA(87.17M)(42.94M)27.15M(72.48M)8.83M
EBITDA Margin-2839.4%-88.4%26.2%-151.1%14.8%
Operating Income(87.97M)(42.2M)21.48M(73.36M)(24K)
Operating Margin-2865.5%-86.9%20.7%-152.9%-0.0%
Interest Income346K1.11M3.94M4.74M2.51M
Interest Expense1.94M2.61M000
Other Income / Expenses(1.79M)(4.22M)3.92M4.8M8.86M
Income Before Tax(89.76M)(46.42M)25.4M(68.57M)8.83M
Pre-Tax Margin-2923.6%-95.5%24.5%-142.9%14.8%
Income Tax Expense002.6M0261K
Net Income(89.76M)(46.42M)22.81M(68.57M)8.57M
Net Margin-2923.6%-95.5%22.0%-142.9%14.4%
EPS (Basic)(2.91)(1.23)0.43(1.27)0.15
EPS (Diluted)(2.91)(1.23)0.43(1.27)0.15
Weighted Avg Shares30.9M37.59M52.7M54.04M56.02M
Weighted Avg Shares (Diluted)30.9M37.59M52.99M54.04M59.04M

Spero Therapeutics, Inc.

NASDAQ:SPRO

Intrinsic Alpha fair value

Locked

Current Price

$0.87

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.